A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia

Seminars in Oncology

Volumn 27, Issue 6 SUPPL. 12, 2000, Pages 99-103

  Saleh, M N ^a   Gutheil, J ^a   Moore, M ^a   Bunch, P W ^a   Butler, J ^a   Kunkel, L ^a   Grillo Lopez A J ^a   LoBuglio, A F ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

ADULT; AGED; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOSE RESPONSE; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL PROTOCOLS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SPLENECTOMY;

EID: 0034468410     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Autoimmune thrombocytopenic purpura
2. Immune thrombocytopenic purpura, neonatal alloimmune thrombocytopenia, and post-transfusion purpura
3. Platelet surface-bound IgG in patients with immune and nonimmune thrombocytopenia
4. Monocyte-platelet interaction in immune and nonimmune thrombocytopenia
5. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura
6. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy
7. Idiopathic thrombocytopenia purpura: A practice guideline developed by explicit methods for the American Society of Hematology
8. Thrombocytopenia due to enhanced platelet destruction by immunologic mechanisms
9. Infection associated with asplenia: Risks, mechanisms, and prevention
10. Overwhelming postsplenectomy infection (OPSI): The clinical syndrome
11. Splenectomy in the treatment of idiopathic thrombopenic purpura in adults. Apropos of 43 cases
12. Therapy of chronic idiopathic thrombocytopenia purpura in adults
13. Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura
14. Intravenous anti-D treatment of immune thrombocytopenic purpura: Analysis of efficacy, toxicity, and mechanism of effect
15. Immune thrombocytopenic purpura: A pilot study of staphylococcal protein A immunomodulation in refractory patients
16. Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases
17. Characterization of a human B lymphocyte-specific antigen
18. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation
19. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation
20. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes
21. 1 phase of the cell cycle
22. Role of the Bp35 cell surface polypeptide in human B-cell activation
23. The CD20 surface molecule of B lymphocytes functions as a calcium channel
24. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains
25. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
26. The anti-tumor effect of monoclonal anti-CD20 antibody (MAB) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines
27. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
28. Rituxan in the treatment of chronic idiopathic thrombocytopenic purpura (ITP)
29. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: Their clinical significance and response to treatment